Vasomune Therapeutics, Inc.

Quick facts

Phase 2 pipeline

• AV-001 · Oncology
  AV-001 is a small molecule that targets the PI3K pathway to modulate immune responses.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Vasomune Therapeutics, Inc. portfolio CI brief
• Vasomune Therapeutics, Inc. pipeline updates RSS